Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

ivary flow were detected for NGX267 in comparison to placebo. These effects increased linearly with dose, were maintained over four days of dosing, and within subject peak increases in salivary flow correlated with peak plasma levels of NGX267.

Decreased salivary flow results in dry mouth, or xerostomia, and is a symptom of a number of underlying conditions. Causes of dry mouth include the autoimmune disorder Sjogren's Syndrome, radiation treatment to the head and neck, and HIV-related salivary gland disease. Xerostomia can also be a side effect of some medications and may be associated with aging.

"The data from this study are promising, given the low incidence of adverse events at potentially therapeutic doses for treating CIAS," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "In addition, the data not only confirm earlier findings that NGX267 increases salivary flow, but also demonstrates that the effect is seen at multiple dose levels and maintained after repetitive dosing. Moving forward, we now have data that suggests that this well-tolerated product candidate could be effective in treating not only CIAS, but also xerostomia. In addition to our planned Phase II study in CIAS, we will consider initiating a small proof of concept study for xerostomia early next year."

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/24/2013)... May 24 (HealthDay News) -- Patients hospitalized for heart ... they,re admitted on Mondays or in the morning, a ... stay are highest among heart failure patients admitted in ... who are scheduled to present their findings Saturday in ... Association of the European Society of Cardiology. ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... used to treat glaucoma may cause droopy eyelids and ... to a new study. The drugs, known as ... pressure, have already been shown to cause blurred vision, ... suggesting that the new findings could lead to labeling ... when prescribing these drugs, the researchers added, particularly as ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV ... consumers compare the features and services offered by ... released the rankings of the best rural ... viewing on their website. , BestSatelliteProviders.com ... Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers ...
Breaking Medicine News(10 mins):Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... ,A new study shows that poor lung function during ... including birth weight, height, and gender. Researchers from Newcastle University ... all aged 14 years. Follow-up data also were obtained for ... showed that several factors were related to poorer lung function ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... 2010 Knee osteoarthritis (OA) accounts for more disability in ... proven cardiovascular and other health benefits, can increase stresses on ... the December 2009 issue of PM&R: The journal of ... knee, hip and ankle joint motions of running barefoot versus ...
... Extremity War Injuries Symposium was held in Washington, D.C., ... surgeons, researchers, experts from governmental agencies, and others to ... Iraq and Afghanistan and to discuss ways to synergize ... summarizing the findings from the symposium is published in ...
... pinpointed the prime factors identifying which elderly persons are ... The researchers, led by Jeffrey M. Lyness, M.D., professor ... in an article in the December issue of The ... for people in the high-risk group hold promise for ...
... , SCOTTSDALE, Ariz., Dec. 31 ... real estate investment trust, announced the completed acquisition of ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... is 100% leased to community hospitals that are wholly-owned ...
Cached Medicine News:Health News:News briefs from the January issue of Chest 2Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Running shoes may cause damage to knees, hips and ankles 2Health News:Extremity war injuries: More research is needed 2Health News:Extremity war injuries: More research is needed 3Health News:Study identifies those elderly most at risk for major depression 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 2Health News:Healthcare Trust of America, Inc. Acquires a 92,500 SF Medical Office Portfolio Located in Texas and Indiana 3
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 700 Series is an advanced three-part ... the abdomen, a pump placed in the scrotum ... corpora cavernosa. It closely simulates the look and ... for innovative penile implant technology, the AMS 700 ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
Medicine Products: